Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAG | P20916 | 1/20 | 0.55 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.49 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.49 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.49 |
| ▸ | HRAS | P01112 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841001 | 1.00 | MAG (0.55) | MAGLGALS8SLC6A2L3MBTL1SSTR5 | |
| SCHEMBL22204678 | 1.00 | MAG (0.55) | MAGLGALS8SLC6A2L3MBTL1SSTR5 | |
| SCHEMBL5841006 | 1.00 | MAG (0.55) | MAGLGALS8SLC6A2L3MBTL1SSTR5 | |
| SCHEMBL24351978 | 0.92 | POLB (0.56) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL7717946 | 0.91 | MAG (0.58) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL16153923 | 0.91 | MAG (0.58) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL542355 | 0.91 | MAG (0.58) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL7717956 | 0.91 | MAG (0.58) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL542353 | 0.91 | MAG (0.58) | MAGLGALS8SLC6A2L3MBTL1HRAS | |
| SCHEMBL15143133 | 0.91 | L3MBTL1 (0.50) | MAGL3MBTL1SSTR5SSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098195-B2 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | HEALTH RESEARCH, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20040058888-A1 | Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides | ALCHEMIA PTY LTD. (AU) | 2004-03-25 | — | — | US | disclosed |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-07 | — | — | US | disclosed |
| EP-1257558-A1 | METHODS FOR SYNTHESIS OF ALPHA-D-GAL (1- 3) GAL-CONTAINING OLIGOSACCHARIDES | Alchemia Pty Ltd (AU) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001051499-A1 | METHODS FOR SYNTHESIS OF α-D-GAL (1→3) GAL-CONTAINING OLIGOSACCHARIDES | ALCHEMIA PTY LTD (AU) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | FUT5, FUT6, OGT | MAG 314/4885LGALS8 98/4885SLC6A2 3485/4885 |
| US-20040058888-A1 | Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides | B4GALT1, B3GAT3, FUT5 | MAG 262/4885LGALS8 65/4885SLC6A2 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.